aTYR PHARMA INC
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 |
| Operating income | -$77.6M | -$67.9M | -$54.9M | -$46.4M | -$34.0M |
| Operating expenses | $77.8M | $68.1M | $55.3M | $56.8M | $34.0M |
| Cash from operations | -$62.0M | -$69.1M | -$33.2M | -$41.9M | -$33.1M |
| Capital expenditure | $77,000 | $65,000 | $4.2M | $1.6M | $192,000 |
| Free cash flow | -$62.1M | -$69.2M | -$37.4M | -$43.5M | -$33.3M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $93.0M | $96.8M | $120.7M | $95.8M | $115.5M |
Shares outstanding 98.1M · Free float 95.2%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.